NCT03135015View on ClinicalTrials.gov

Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

June 21, 2017

Study Completion Date

June 21, 2017

Conditions
Insulin Resistance, Diabetes
Interventions
OTHER

Placebo capsules

250ml water with 16 x 250mg placebo capsules

OTHER

2g capsules

250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules

OTHER

4g capsules

250ml water with 16 x 250mg capsules containing Axulin powder

OTHER

Water Control

250ml water

OTHER

2g tablets

250ml water with 2 x 1g tablets containing Axulin powder

OTHER

4g tablets

250ml water with 4 x 1g tablets containing Axulin powder

Trial Locations (1)

M5C 2N8

Glycemic Index Laboratories, Inc., Toronto

Sponsors
All Listed Sponsors
collaborator

Glycemic Index Laboratories, Inc

INDUSTRY

lead

Housey Healthcare ULC

INDUSTRY